



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/087,942	03/05/2002	Robert L. Campbell	41552	8014

26253 7590 01/13/2006

DAVID W. HIGHET, VP AND CHIEF IP COUNSEL
BECTON, DICKINSON AND COMPANY
1 BECTON DRIVE, MC 110
FRANKLIN LAKES, NJ 07417-1880

EXAMINER

BRUSCA, JOHN S

ART UNIT PAPER NUMBER

1631

DATE MAILED: 01/13/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

10/087,942

Applicant(s)

CAMPBELL ET AL.

Examiner

John S. Brusca

Art Unit

1631

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 28 October 2005.
- 2a) ☒ This action is FINAL. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 2-128 is/are pending in the application.
- 4a) Of the above claim(s) 16, 17 and 31-127 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 2-15 and 18-30 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☒ Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date 5/23/05, 8/26/05.
- 4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____.
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☐ Other: _____.

DETAILED ACTION

Sequence Rule Compliance

1. The sequence listing filed 28 October 2005 has been entered into the specification.

Priority

2. The amendment to the first sentence of the specification filed 28 October 2005 has been entered and perfects the applicant's claim for priority under 35 U.S.C. § 120.

Claim Rejections - 35 USC § 112

3. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

4. Claim 30 is rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.

In *In re Wands* (8 USPQ2d 1400 (CAFC 1988)) the CAFC considered the issue of enablement in molecular biology. The CAFC summarized eight factors to be considered in a determination of "undue experimentation." These factors include: (a) the quantity of experimentation necessary; (b) the amount of direction or guidance presented; (c) the presence or absence of working examples; (d) the nature of the invention; (e) the state of the prior art; (f) the relative skill of those in the art; (g) the predictability of the art; and (h) the breadth of the claims.

In considering the factors for the instant claims:

a) In order to practice the claimed invention one of skill in the art must assay for the effect of a peptide library on alteration of production of antibiotics, steroids, carbohydrates, lipids, and nucleic acids in cultured cells. For the reasons discussed below there would be an unpredictable amount of experimentation required to use the claimed method.

b) The specification does not present specific guidance for practicing the claimed method.

c) The specification does not present working examples of the claimed method.

d) The nature of the invention, screening of the effect of peptide libraries, is complex.

e) A search of the prior art did not reveal use of peptides to alter production of antibiotics, steroids, carbohydrates, lipids, and nucleic acids in cultured cells.

f) The skill of those in the art of cell culture assays is high.

g) The prior art does not predict whether the claimed method can be used.

h) The claims are broad in that they are drawn to a method without experimental support that shows that it can be used.

The skilled practitioner would first turn to the instant specification for guidance in practicing the claimed method, however the specification does not provide such guidance. The skilled practitioner would next turn to the prior art for such guidance, however the prior art does not show such guidance. Finally, said practitioner would turn to trial and error experimentation to practice the claimed method. Such represents undue experimentation.

5. Applicant's arguments filed 28 October 2005 have been fully considered but they are not persuasive. The applicants state that the claimed method can identify peptides, proteins, carbohydrates, nucleic acids, and lipids, and point to paragraphs 22, 63, and 150 for support in

Art Unit: 1631

the specification. However there are no paragraph numbers in the specification as filed. The applicants do not provide reasoning to rebut the rejection of claim 30 for lack of enablement. It is further noted that claim 30 requires identification of culture medium components that alter production of antibiotics, steroids, carbohydrates, lipids, and nucleic acids. Claim 30 is not drawn to identification of peptides, proteins, carbohydrates, nucleic acids, and lipids. The applicant's statement does not address the merits of the rejection.

Claim Rejections - 35 USC § 102

6. The rejection of claim 128 and dependent claims 3-10, 13-15, and 18-28 under 35 U.S.C. 102(b) as being anticipated by Lam et al. (U.S. Patent No. 5,510,240 as further evidenced by Invitrogen catalog in the Office action mailed 28 April 2005 is withdrawn in view of the amendment filed 28 October 2005.

Claim Rejections - 35 USC § 103

7. The rejection of claims 128 and 2 under 35 U.S.C. 103(a) as being unpatentable over Lam et al. in view of Bause in the Office action mailed 28 April 2005 is withdrawn in view of the amendment filed 28 October 2005.

8. The rejection of claims 128, 11, and 12 under 35 U.S.C. 103(a) as being unpatentable over Lam et al. in view of Vyas et al. in the Office action mailed 28 April 2005 is withdrawn in view of the amendment filed 28 October 2005.

9. The rejection of claims 128, 19, 23, 28, and 29 under 35 U.S.C. 103(a) as being unpatentable over Lam et al. in view of Davis et al. in the Office action mailed 28 April 2005 is withdrawn in view of the amendment filed 28 October 2005.

Art Unit: 1631

10. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

11. This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

12. Claims 2-10, 13-15, 18-28, and 128 are rejected under 35 U.S.C. 103(a) as being unpatentable over Lam et al. in view of Zheng et al. in view of Bause as evidenced by Invitrogen catalog.

The claims are drawn to a method of characterizing (including space-filling design methods) and screening a first library of compounds by assaying the effect of members of the library in culture medium by measuring an effect of the compounds on the properties of the media. The property of the medium is correlated with a property of the compound. A second library of compounds not present in the first library of compounds that meets a predetermined range of properties as assessed in the first screen is then constructed and screened in media. The second screen is used to select a culture medium component with desired properties. In some embodiments the property of the medium is a function of the property and the compound

Art Unit: 1631

assayed. In some embodiments the second screen includes compounds analyzed by space-filling techniques. In some embodiments the property of the compound is sequence-specific, a whole molecule parameter, or a molecular weight. In some embodiments the compounds are peptides with at least one residue of limited variability. In some embodiments the medium is seeded with mammalian cell cultures and a property of the medium is growth of the cell culture or altered peptide or protein production. In some embodiments the culture medium is a synthetic medium.

Lam et al. shows in columns 21 and beyond assays of random peptide libraries on beads added to cells in growth media. The peptides are released from the beads to the media and the cultures are assayed for modulation of growth or other parameters. Lam et al. shows a second round of screening of variants of the first library in column 17 lines 18-24. Lam et al. shows assay of cytokine release (a polypeptide) from assayed cultures in column 22 line 60 to column 23 line 3, and measurement of toxicity in column 23 lines 3-14, and screening for peptide inhibitors of tumor cell growth in column 45-46. The sequence (and therefore the molecular weight and structure of the entire peptide) is assayed in columns 27-28. Multiple properties of the peptide library are detected in the examples in columns 41-46. Insertion of non-variable residues in the random peptide sequence is shown in column 8, lines 30-32 and column 40. The results of the assays show that the property of the medium is a function of the particular peptide in the medium. Lam et al. shows use of RPMI medium in column 45, but does not show that RPMI medium is a synthetic medium. Lam et al. does not show use of space-filling analysis to measure properties. Lam et al. does not show determination of parameters of the first library before screening, or of determining functions of quantitative structure activity relationships (QSAR) analysis.

Invitrogen catalog shows the content of RPMI medium. Invitrogen catalog shows that RPMI medium consists entirely of defined compounds.

Zheng et al. shows in the abstract and throughout a method of constructing and refining a peptide library by use of QSAR analysis. Zheng et al. states in the abstract that their method allows for construction of libraries that are most likely to have a desired activity. Library members are selected by use of a pre-constructed QSAR equation. Figure 1 shows that the method can be iterative to different libraries, as further illustrated in the discussion of library optimization on pages 4-6.

Bause shows analysis of peptide sequences that are sites of glycosylation can be aided by consideration of space-filling parameters in figures 2-4 and pages 333-335.

It would have been obvious to a person of ordinary skill in the art at the time the invention was made to employ space-filling techniques to analyze the selected peptides of Lam et al. because Bause shows that such analysis is useful to determine properties of peptides. It would have been further obvious to use the QSAR methods of Zheng et al. to characterize a first and second library because Zheng et al. shows that such analysis allows for selection of library members that are most likely to have a desired activity.

13. Claims 11, 12, and 128 are rejected under 35 U.S.C. 103(a) as being unpatentable over Lam et al. in view of Zheng et al. in view of Vyas et al.

The claims are drawn to a method of characterizing (including space-filling design methods) and screening a first library of compounds by assaying the effect of members of the library in culture medium by measuring an effect of the compounds on the properties of the media. The property of the medium is correlated with a property of the compound. A second

Art Unit: 1631

library of compounds not present in the first library of compounds that meets a predetermined range of properties as assessed in the first screen is then constructed and screened in media. The second screen is used to select a culture medium component with desired properties. Claims 11 and 12 are drawn to use of isomers of compounds and space-filling analysis in the method of claim 128.

Art Unit: 1631

Lam et al. shows in columns 21 and beyond assays of random peptide libraries on beads added to cells in growth media. The peptides are released from the beads to the media and the cultures are assayed for modulation of growth or other parameters. Lam et al. shows a second round of screening of variants of the first library in column 17 lines 18-24. Lam et al. shows assay of cytokine release (a polypeptide) from assayed cultures in column 22 line 60 to column 23 line 3, and measurement of toxicity in column 23 lines 3-14, and screening for peptide inhibitors of tumor cell growth in column 45-46. The sequence (and therefore the molecular weight and structure of the entire peptide) is assayed in columns 27-28. Multiple properties of the peptide library are detected in the examples in columns 41-46. Insertion of non-variable residues in the random peptide sequence is shown in column 8, lines 30-32 and column 40. The results of the assays show that the property of the medium is a function of the particular peptide in the medium. Lam et al. shows use of RPMI medium in column 45, but does not show that RPMI medium is a synthetic medium. Lam et al. does not show use of space-filling analysis to measure properties or use of compound isomers. Lam et al. does not show determination of parameters of the first library before screening, or of determining functions of quantitative structure activity relationships (QSAR) analysis.

Vyas et al. shows that the structure at the amino terminus of a particular peptide is important for receptor binding in the abstract and throughout. Optical isomers of peptides are studied on page 3608 to analyze the binding activity of the peptide. Space filling parameters of peptides are shown in figure 5 to further study structural requirements of binding activity.

It would have been further obvious to use the QSAR methods of Zheng et al. to characterize a first and second library because Zheng et al. shows that such analysis allows for

Art Unit: 1631

selection of library members that are most likely to have a desired activity. It would have been obvious to a person of ordinary skill in the art at the time the invention was made to employ space-filling techniques and peptide isomers to analyze the selected peptides of Lam et al. because Vyas et al. show that such analytical techniques are useful to study relationships between peptide structure and activity.

14. Claims 19, 23, 28, 29 and 128 are rejected under 35 U.S.C. 103(a) as being unpatentable over Lam et al. in view of Zheng et al. in view of Bause as evidenced by Invitrogen catalog as applied to claims 2-10, 13-15, 18-28, and 128 and further in view of Davis et al.

Lam et al. in view of Zheng et al. in view of Bause as evidenced by Invitrogen catalog as applied to claims 2-10, 13-15, 18-28, and 128 does not show the effect of a library of compounds on toxin production.

Davis et al. shows on pages 685-686 that *Corynebacterium diphtheriae* toxin is a polypeptide. Davis et al. show throughout that toxin causes a serious disease in humans by blocking protein synthesis.

It would have been obvious to a person of ordinary skill in the art at the time the invention was made to modify the method of Lam et al. in view of Zheng et al. in view of Bause as evidenced by Invitrogen catalog as applied to claims 2-10, 13-15, 18-28, and 128 to determine the effect of a library of compounds on toxin production because Davis et al. shows that *Corynebacterium diphtheriae* toxin is a polypeptide that causes a serious disease in humans and modulation of toxin production would modulate disease in humans.

Conclusion

15. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire **THREE MONTHS** from the mailing date of this action. In the event a first reply is filed within **TWO MONTHS** of the mailing date of this final action and the advisory action is not mailed until after the end of the **THREE-MONTH** shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than **SIX MONTHS** from the date of this final action.

16. This application contains claims 16, 17, and 31-127 drawn to an invention nonelected with traverse in the election filed 22 January 2004. A complete reply to the final rejection must include cancellation of nonelected claims or other appropriate action (37 CFR 1.144) See MPEP § 821.01.

17. Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of

Art Unit: 1631

the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public.

For all other customer support, please call the USPTO Call Center at (800) 786-9199. Any inquiry concerning this communication or earlier communications from the examiner should be directed to John S. Brusca whose telephone number is 571 272-0714. The examiner can normally be reached on M-F 8:30 AM - 5:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ardin Marschel, PhD. can be reached on 571 272-0718. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

John S. Brusca
Primary Examiner
Art Unit 1631

John S. Brusca
5 January 2006

jsb